Acne Vulgaris - Opportunity Analysis and Forecasts to 2018


Published on

Market Research Reports, Inc. has announced the addition of “OpportunityAnalyzer: Acne Vulgaris - Opportunity Analysis and Forecasts to 2018” research report to their offering. See more at-

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Acne Vulgaris - Opportunity Analysis and Forecasts to 2018

  1. 1. Category : Pharma & Healthcare All logos and Images mentioned on this slide belong to their respective owners.
  2. 2. Introduction to Report  Launch Date: June 20, 2014  Number of Pages: 177  Geography Coverage: Global  Available Format: PDF Price For Single User License: USD 5,995 Price For Site License: USD 11,990 Price For Global User License: USD 17,985 Delivery Time: Within 24 Hours (During Working Days)
  3. 3. About the Report Despite its considerable patient population, the acne market has been overlooked and remained stagnant for the last decade. There has been a lack of research efforts due to the perception of a poor return on investment for topical treatments, the mainstay of acne therapy. There is an array of treatment options for acne, though with the exception of isotretinoin, most only provide symptomatic relief as opposed to a curative or disease- modifying solution.
  4. 4. Research Findings The main drivers of growth in the acne market during the 2012- 2018 forecast period include the launch of AndroScience’s ASC- J9, a therapeutic that is highly anticipated in the previously stagnant acne market and will make hormonal therapies available to males with acne, the continued success and uptake of Galderma’s Epiduo, and the launch of Photocure’s Visonac; potentially the first photodynamic therapy for use in acne. The lack of dedicated R&D programs in acne has been attributed to pharmaceutical companies viewing topicals, the mainstay of acne therapy, as being inexpensive, with a poor return on investment. Instead, R&D strategies have centered on reformulations of existing products and/or fixed-dose combination therapies, acquisitions of key dermatology products by Big Pharma, and label expansions into the previously untapped pediatric market.
  5. 5. Research Findings Continues… A continued unmet need for acne is the need for new and innovative products to treat the underlying condition. Ideally, these products should be molecules that can specifically target critical pathways in the acne pathophysiology. Given the acne market’s substantial patient pool (estimated to be 103.9 million patients in the US and 5EU) and increasing understanding of the disease’s pathophysiology. Publisher estimates the 2012 pharmacological therapy sales for acne to total approximately $2.3 billion across the six major pharmaceutical markets (6MM) covered within this report: the US, France, Germany, Italy, Spain, and the UK. The US contributes 91% of these sales, generating an estimated $2.1 billion in 2012. With $207.0m in sales from the 5EU, Germany was the largest market with an estimated $54.3m in sales in 2012.
  6. 6. Research Findings Continues… By the end of the forecast period in 2018, acne sales are forecast to reach over $2.8 billion, growing at a compound annual growth rate (CAGR) of 3.9% over the six-year forecast period. The majority of sales will come from the US, which will maintain its 2012 lead and command 93% of the market in 2018. Another corporate trend is the strategic acquisition of key dermatology products by Big Pharma. A notable event in 2009 involved the acquisition of Stiefel, a leading dermatology company, by GSK for $3.6 billion.
  7. 7. Scope Overview of acne, including epidemiology, etiology, pathophysiology, symptoms, and current treatment options. Annualized acne prescription therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 to 2018. Key topics covered include strategic product assessment, market characterization, unmet needs, R&D strategies, clinical trial design, and benchmarking analysis for the acne prescription therapeutics market. Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late stage pipeline drugs. Accompanied by an interactive clinical and commercial benchmarking analysis tool. Analysis of the current and future market competition in the US and 5EU acne prescription therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
  8. 8. Report Coverage 1. Table of Contents 2. Introduction 3. Disease Overview 4. Epidemiology 5. Current Treatment Options 6. Unmet Needs Assessment and Opportunity Analysis 7. R&D Strategies 8. Pipeline Assessment 9. Pipeline Valuation Analysis 10.Appendix For more details regarding Report coverage see the last slide All logos and Images mentioned on this slide belong to their respective owners.
  9. 9. Custom Research:  Are you an industry professional, entrepreneur, venture capitalist, investors and organization, then let us know your specific research requirements. Our goal is to cater to your requirements be it for a custom market research project, syndicated research report on a specific market or industry sector, newsletter creation, case study development or anything else related to marketing research. For Any Customization Related query Visit IdeaCenter @
  10. 10. How To Buy This Report? Visit following URL to see Table of Content and purchase this publication: About Market Research Reports, Inc. Market Research Reports provides a customized set of reports from reputed Publishers, built on the intelligence available within organizations and leverages on our motto of “Intelligence Redefined”. Contact : Amitava Sen Email : Phone: +1 302-703-7787 (USA) +91-8762746600 (India)